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Stlmmal~ 
The pleiotropic cytokine interleukin 6 (IL-6) plays a role in the pathogenesis of various diseases, 
such as multiple myeloma, autoimmune and inflammatory diseases and osteoporosis. Therefore, 
specific inhibitors of IL-6 may have clinical applications. We previously succeeded in developing 
receptor antagonists of IL-6 that antagonized wild-type IL-6 activity on the human Epstein-Barr 
virus (EBV)-transformed B cell line CESS and the human hepatoma cell line HepG2. However, 
these proteins still had agonistic activity on the human myeloma cell line XG-1. We here report 
the construction of a novel mutant protein of IL-6 in which two different mutations are combined 
that individually disrupt  the association  of the IL-6/IL-6 receptor  (R)ot  complex with the 
signaltransducing "B" chain, gp130, but leave the binding of IL-6 to IL-6Rot intact. The resulting 
mutant protein (with substitutions  of residues Gin160 to Glu, Thr163 to Pro, and replacement 
of human residues Lys42-Ala57 with the corresponding residues of mouse IL-6) was inactive 
on XG-1 cells and weakly antagonized wild-type IL-6 activity on these cells. By introducing 
two additional substitutions  (Phe171Leu, Ser177Arg), the affinity of the mutant protein for IL- 
6Rot was increased fivefold, rendering it capable of completely inhibiting wild-type IL-6 activity 
on XG-1 cells. Moreover, this mutant also antagonized the activity of IL-6, but not that of leukemia 
inhibitory factor, oncostatin M,  or GM-CSF  on the human erythroleukemia cell line TF-1, 
demonstrating its specificity for IL-6. These data demonstrate the feasibility of developing specific 
IL-6R antagonists. The availability  of such antagonists may offer an approach to specifically  inhibit 
IL-6 activity  in vivo. 
I 
nterleukin 6 (IL-6) is a pleiotropic cytokine that acts on 
wide variety of cells, exerting cellular proliferation, growth 
inhibition, and specific gene expression, sometimes accom- 
panied by cellular differentiation (1). IL-6 has been suggested 
to be involved in the pathogenesis of several diseases, including 
inflammatory and autoimmune disorders and lymphoid malig- 
nancies (1). Indeed, specific inhibition of IL-6 in vivo by ad- 
ministration of neutralizing anti-IL-6  mAbs had beneficial 
effects in multiple myeloma, rheumatoid arthritis, Castleman's 
disease, and in experimental  models  for sepsis (2-6). 
The IL-6 signal is transduced after homodimerization of 
a  nonligand-binding  signal  transducer,  gp130 (IL-6R3), 
which becomes associated with an 80-kD IL-6-binding chain 
(IL-6Rot) in the presence of IL-6 (1). Gp130 also transduces 
signals delivered by oncostatin M  (OM), leukemia inhibi- 
tory factor (LIF), ciliary neurotrophic factor, and IL-11, in 
addition to those of IL-6, explaining the functional redun- 
dancy of these cytokines  (for review see 7). 
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We have previously identified two regions of IL-6, distinct 
from the IL-6Roe binding site, which are important for IL-6 
biological activity (8, 9). Mutations in each of these regions 
have little effect on IL-6-IL-6Ro~ binding, but disrupt the 
association of the IL-6/IL-6Rc~ complex with IL-6tLS. For 
purpose of clarity these regions are here designated 31 and 
32.  The /31  region consists  of residues Gln153-His165 of 
IL-6. Some IL-6.B1 mutant proteins  with substitutions  of 
Trp158 to Arg or Gln160 to Glu, combined with Thr163 
to Pro (IL-6.W158R/T163P  or IL-6.Q160E/T163P),  can an- 
tagonize the biological  activity of wild-type (wt) IL-6 on 
the human EBV-transformed B cell line CESS and the human 
hepatoma cell line HepG2 (8 and de Hon, F. D., E. ten Boekel, 
J. Herrman, C. Clement, M. Ehlers, T. Taga, K. Yasakawa, 
Y. Ohsugi, T. Kishimoto, S. Rose-John,  et al., manuscript 
submitted for publication).  The 32 region was identified by 
studying human/mouse chimeric proteins of IL-6 and is com- 
posed of residues Lys42-Ala57 (9). An IL-6.32 mutant pro- 
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the corresponding residues of mouse IL-6, had an ,,ol,000- 
fold reduced specific activity in various bioassays, but displayed 
no antagonistic activity (9). 
,Recently we found that the IL-6./~1 antagonistic mutant 
proteins had residual agonistic activity on the human my- 
eloma cell line XG-1. This activity could be inhibited with 
anti-gp130 mAb, but could not be eliminated by extensive 
mutagenesis of the B1 region,  suggesting that other parts 
of IL-6 that are important for association with gp130, might 
be involved (de Hon, et al., manuscript submitted for publi- 
cation). Although the ~/t and ~/2 regions are closely spaced 
in the putative tertiary structure of IL-6 (9),  experimental 
evidence suggested that they are functionally distinct (de Hon, 
et al., manuscript submitted for publication). Combining a 
B1 with a ~2 region mutant might therefore result in an IL-6 
variant devoid of activity on XG-1 cells and with antagonistic 
properties.  To  test  this  hypothesis,  the  mutations  of the 
IL-6.31 mutant protein Q160E/T163P  have here been com- 
bined with those of the above described IL-6,32 mutant pro- 
tein and the biological activity and receptor binding charac- 
teristics of the resulting protein (IL-6.3t,2) were examined. 
Materials and Methods 
Cytokines.  The wt II~6 preparation used as a standard was ma- 
ture recombinant human (rh) IL,6 (Alal-Met185) purified from Esch- 
erichia coli BL21 (DE3) carrying the pETSc-hlL-6 cDNA expres- 
sion vector (8). E. coli-derived rhOM and rhLIF were obtained from 
PreproTech (Rockyhill, NJ), hGM-CSF was from Sandoz Ltd. (Basel, 
Switzerland). 
Construction of Expression  Vectors.  The  T7  promoter  vector 
pRSET6D was used for expression of IL-6 mutant proteins (a kind 
gift of T. Stoyan, Institut fiir Biochemie der Rheinisch Westf'~lischen 
Technischen Hochschule, Aachen, Germany). The construction of 
expression  vectors  encoding  the  Ib6./~1 mutant  protein  (IL- 
6.Q160E/T163P)  and  the Ib6.~82 mutant protein  (a mutant in 
which human Lys42-Ala57 is exchanged with the corresponding 
mouse residues) has been described (8, 9). The vector pRSET-Ib 
6./~1,2 was constructed by ligating an NcoI-XbaI IL-6 cDNA frag- 
ment from pRSET-IL-6.B2 carrying the  IL-6./32 mutations into 
NcoI-XbaI-digested  pRSET-IL-6.Bt.  To  construct  pRSET-IL- 
6.B1,2,  Phe171Leu/Ser177Arg,  (short  designation:  pRSET-Ib 
6.B1,2/LR), and XbaI-Bsu36I fragment encoding the Phe171Leu 
and Ser177Arg substitutions was created with PCR technology 
by  using  pRSET-II~6.~I.2  as  a  template  and  subcloned  into 
XbaI-Bsu36I  digested pRSET-IL-6./31.2. PCR was carried out with 
Pfu polymerase (Stratagene, La Jolla, CA) following standard proce- 
dures (denaturation, 1.5 rain 95~  annealing I min 55~  exten- 
sion,  1 min 72~  30 cycles) and the following primers:  a sense 
primer carrying the XbaI site (5'-GAA TCT AGA TGC AAT AAC 
CAC C-3'), and an antisense primer encoding the two substitu- 
tions and the Bsu36I site (5'-GAA GAG CCC TCA GGC TGC 
GCT GCA GGA ACT CCT TAA GGC TGC GCA GAA TG-3'). 
The integrity of the constructs was verified by restriction enzyme 
digestion and nucleotide sequence analysis on dsDNA with the 
dideoxy chain termination method by using the  sequenase kit 
(United States Biochemical Corp., Cleveland,  OH). 
Expression and Purification of lL-6 Mutant Proteins.  For expres- 
sion of the IL-6 mutant proteins, the vectors were transformed to 
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E. coli BL21(DE3) and the proteins  were purified from inclusion 
bodies and quantified as described (8, 9). 
11_,6 Bioassays.  The human XG-1 myeloma proliferation  assay 
was performed as described (10). The human erythroleukemia cell 
line TF-1 (kindly provided by Dr. R. Kastelein, DNAX, Palo Alto, 
CA) was maintained in IMDM supplemented  with 5% vol/vol 
FCS,  5  ￿  10 -s M  2-ME,  100 IU penicillin,  100 #g/ml strep- 
tomycin, 20 #g/ml human transferrin  (Behringwerke,  Marburg, 
Germany) (IMDM-5% FCS-Trf), and 3 ng/ml hGM-CSF.  To re- 
move hGM-CSF, TF-1 cells were washed twice with Earle's, 10% 
vol/vol FCS, incubated  for 3 h at 37~  in IMDM-5% FCS-Trf, 
and washed again. TF-1 cells were then incubated in 96-well flat- 
bottomed microtiter plates  (2  ￿  104 cells/well)  in triplicate  in 
RPMI 1640, 5% vol/vol pooled human serum, and supplements 
for 40 h in the presence of serial dilutions of the samples to be 
tested. After this culture period, the cells were pulse-labeled with 
7.4 kBq of [3H]thymidine  (74 Gbq/mmol) for 5 h and the radio- 
activity incorporated  in the nuclei was measured. 
Receptor Binding Assays.  To investigate the binding of IL-6 mu- 
tant proteins to IL-6Rc~, an ELISA was used in which the capacity 
of the IL-6 mutant proteins was measured to compete for binding 
of biotinylated IL-6 to immobilized soluble (s) IL-6Ror  (de Hon 
et al., manuscript submitted for publication). Briefly,  purified wtlL-6 
was biotinylated by using LC-biotin-N-hydroxysuccinimide  ester 
(Pierce Chemical Co., Rockford, IL) following the manufacturers 
instructions. Microtiter plates (maxisorb;  Nunc, Roskilde,  Den- 
mark) were coated overnight with anti-IL-6Rc~ mAb MT18  (3 
/~g/ml in PBS; reference 11). The plates were washed with PBS, 
0.02%  Tween-20 (PT) and incubated for 2 h with conditioned 
medium of NIH-3T3 fibroblasts expressing the slL-6Rot (12). After 
washing, serial dilutions of the mutants, together with 8 ng/ml 
of biotinylated wt IL-6, were incubated in duplicate at room tem- 
perature until binding reached equilibrium (>2 h). The wells were 
subsequently emptied and bound biotinylated wt IL-6 was detected 
with poly-horseradish  peroxidase streptavidin (poly HRP; Janssen 
Biochimica,  Weers, Belgium)  without  further  washing.  After 
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Figure  1.  Biological  activity of IL-6.~1, -~82, and -~81.2 on the human 
myeloma  cell  line XG-1 and erythroleukemia  cell  line TF-1. XG-1 and TF-1 
cells were cultured for 3 and 2 d, respectively,  in the presence of wt 11.-6, 
Ib6.Bt, IL-6.~2, or IL-6.B1,2  at the indicated concentrations and the in- 
duced proliferation  was measured by tritiated thymidine incorporation. 
Data points represent mean cpm of triplicate  cultures. The SD was gener- 
ally <10% of these values for the XG-1 assay and <25% for the TF-1 
assay. One representative experiment out of three is shown. 
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Figure 2.  Binding  of IILr6./~t, -/~2, and "/~;,2  to slIr6Kot and slD6R~. 
(/1) Competitive inhibition of the binding of 8 ng/ml of  biotinylated Ib6 
to slL-6K<x  by increasing concentrations of wt IL-6, IL-6./31, Ib6./~2, or 
IL-6./~1.2. (B) sIL-6R~IgG1 fusion protein was incubated with increasing 
concentrations of the mutant proteins and immobilized sIL-6Kcz. Bound 
fusion protein was detected with a peroxidase conjugated mouse mAb 
anti-human IgG. Control, a mutant protein with mutations in the lit 
6Rex binding site (Arg180Ser,  Ah181Arg, and a deletion  of the four COOH- 
terminal amino acid residues). The average values of duplicate measure- 
ments are shown of one representative experiment out of three. 
washing  with PT, bound poly HRP  was  finally  detected with 
3,Y,5,5'-tetramethylbenzidine  (TMB; Merck, Darmstadt, Germany) 
staining as described  (8). 
To measure the capacity of the IL-6 mutant proteins to induce 
the IL-6Rc~-dependent association  with IL-6RB, an ELISA was 
used with immobilized slL-6Rc~ and a fusion protein consisting 
of 605 amino acids of the extracellular domain of gp130 (including 
the 22-amino acid signal peptide), fused to the hinge region and 
last two constant region domains of human IgG1 (slL-6RB-IgG1). 
Construction of the vector encoding this protein and its expres- 
sion in COS-7 cells will be described  elsewhere (Ebeling,  S. B., 
manuscript in preparation). For the ELISA, microtiter plates were 
coated with mAb MT18, washed, and incubated with slL-6Rc~ 
as described above. After washing, various concentrations of IL-6 
mutant proteins together with culture supernatant from COS-7 
cells transfected with the slL-6RB-IgG1 expression vector were 
added for 2 h. After this incubation period, wells were emptied 
and bound slL-6RB-IgG was  detected with a HRP-conjugated 
mouse mAb specific for human IgG (MH16-1ME; Central Labora- 
tory of the Netherlands Red Cross Blood Transfusion Service, Am- 
sterdam, The Netherlands), without intermediate washing. Bound 
conjugate was subsequently detected after extensive washing with 
PT, as described above. 
Results 
IL-6.f11,2 Is Inactive on Human Myeloma and Erythroleukemia 
Cells.  We tested the biological activity of the IL-6.Bl.2 mu- 
tant protein on the human myeloma cell line XG-1 and the 
human erythroleukemia cell line TF-1 (Fig.  1).  In contrast 
to the IL-6.~1 and IL-6.~/2 mutant proteins, which displayed 
an  ",d,000-fold reduced  specific activity in the  assays,  the 
IL-6.~1.2 double mutant  protein was completely devoid of 
activity on XG-1  and  TF-1 cells. 
IL-6.fll,2 Binds  to IL-6Rcr But Not to IL-6Rfl.  IL-6 can 
bind to a soluble form of the extracellular domain of IL-6Rcx 
(slL-6Ro 0  with  similar  affinity as  to  the transmembrane 
receptor (13). Also, in the presence of the soluble extracel- 
lular domain of IL-6RB (slL-6RB), ternary complex forma- 
tion between IL-6, slL-6Rcx, and slL-61~ can be detected 
(14). We therefore employed ELISAs with slL-6R compo- 
nents to investigate the receptor binding  characteristics of 
the IL-6 mutant proteins. As shown before, the IL-6.B1 and 
IL-6.~2 mutant proteins had a similar affinity for slL-6Ro~ 
as wt  IL-6, whereas the interaction with sIL-6R.~ was  se- 
verely impaired (Fig. 2; references 8, 9). The binding charac- 
teristics of the IL-6.~t,2 mutant protein were similar to those 
of the individual mutants, with a small (fivefold) reduction 
in affinity for sIL-6P,  cz (Fig.  2).  In contrast to the lack of 
reactivity of IL-6.~1.2 with  slL-61~,  we reproducibly ob- 
served some residual reactivity of IL-6./3i and IL-6.~2. This 
might explain why the individual mutant proteins retained 
activity on XG-1 and TF-1 cells, whereas the double mutant 
was inactive. Thus, despite of its ability to form a complex 
with IL-6P,  cz, the IL-6.B1,2  protein is inactive in XG-1 and 
TF-1  assays  because it is unable  to  associate with  IL-61LB 
and induce dimerization  thereof. 
IL-6.fll,2  and IL-6.~I,2/LR  Act  as IL-6R  Antagonists  on 
XG-I  Cells.  The binding  properties of the IL-6.310 pro- 
tein suggested that it might antagonize wt IL-6 activity on 
XG-1  and  TF-1  assays.  Indeed,  the  IL-6.3z,2  protein  in- 
hibited wt IL-6 activity on XG-1 cells to ~40%, when tested 
at a concentration of 10 #g/ml (Fig. 3). To increase the an- 
tagonistic capacity of the IL-6.~1,2 mutant protein we sub- 
sequently  introduced  two  substitutions  (Phe171Leu  and 
Ser177Arg) in the COOH  terminus of the molecule.  Indi- 
vidually,  these substitutions  had been reported  to increase 
the affinity for IL-6Ro~ by approximately two- to threefold 
(15,  16).  The resulting  mutant  protein  IL-6./3t,2/LR  dis- 
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Figure 3.  Inhibitory  effect  of IL-6./~1.2  and IL-6.B1.2/LR  on the wt lI~6 
induced proliferation of XG-1 cells. The indicated concentrations of 
ID6.B1.2 and Ib6./~I.2/LR were added at the onset of the cultures in the 
presence of 100 pg/ml wt IL-6. Maximum proliferation induced by wt 
IL-6 was 20,614 _+ 938 cpm ~  _+ SD). Background  proliferation  (3,285 _+ 
825 cpm) was subtracted. One representative  of two experiments  is shown. 
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Figure  4.  Effect of IL-6.~I,z/LK on the proliferation  of TF-1 cells in- 
duced by various cytokines. TF-1 cells  were incubated for 2 d with or without 
I ng/ml of wt lb6, OM, LIF, or hGM-CSF in the presence of increasing 
concentrations  of I1:6.BI,2/LK. Data are expressed as a percentage of the 
maximal proliferation induced by each cytokine in the absence of II~./~1,2/ 
LR. Maximal  cpm (x  •  SD): wt II:6; 2,913  •  1,070, OM, 3,576  + 
296; LIE 5,233  _+  922; and hGM-CSF,  36,050  •  1,164. The mean of 
triplicate  measurements  of one representative  experiment  out of two is 
shown. 
played a fivefold increased affinity of slL-6Rc~ compared with 
IL-6.~/1,2 (data not shown). This mutant protein completely 
inhibited wt IL-6 activity on XG-1 cells when used at a 10  s- 
fold molar excess (Fig. 3). The inhibition could be reversed 
by adding increasing concentrations of wt IL-6, demonstrating 
that antagonism by the mutant protein preparation was not 
due to an aspecific toxic effect (data not shown). 
IL-6.fll,2/LR  Specifically Inhibits IL-6 Activity on TF-I Cells. 
We next measured the capacity of the IL-6.Bt,2/LR mutant 
protein to inhibit the proliferation of TF-1 cells induced by 
wt IL-6, LIF, OM, and GM-CSE Whereas the IL-6-induced 
proliferation was completely abrogated by the mutant protein, 
the proliferation induced by the other cytokines was unaffected 
(Fig. 4). Thus, the IL-6.~I,2/LR protein can completely and 
specifically antagonize the biological  activity of wt IL-6 on 
XG-1  and TF-1 cells. 
Discussion 
To elucidate the mechanism of IL-6-receptor interaction 
and to generate IL-6 variants with potential therapeutic value, 
we and others study the structure-function relationships of 
human IL-6. Three regions of IL-6 have now been identified 
that are involved in the IL-6Rc~-dependent association of IL-6 
with IL6KB: the B1 and B2 regions described here and a re- 
cently described third region (provisionally designated B3) 
that is composed of residues Tyr31 and Gly35 (17, Tyr32 and 
Gly36 in our numbering). Individually mutating the/31, but 
not  the  ~/2  region,  renders  partial  receptor  antagonists, 
which inhibit IL-6 activity on a human EBV-transformed 
B cell line (CESS)  and on hepatoma cell line HepG2, but 
not on XG-1 and TF-1 ceils (8, 9; and de Hon et al., manu- 
script submitted for publication).  For a f13 mutant protein 
partial antagonism on the human hepatoma cell line Hep3B 
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was shown (17). It is here demonstrated that combining B1 
and B2 mutations results in an  IL-6 variant  that  is com- 
pletely inactive on both the human IL-6 responsive cell lines 
XG-1 and TF-1 and the cell lines CESS and HepG2 and can 
antagonize IL-6 activity on these cells (Fig.  1 and data not 
shown). It will be interesting to test whether combining the 
B3 mutations with the ~/t and/or ~2 mutations gives similar 
results. 
It is at present unclear what the exact roles of the ~/regions 
are in IL-6-receptor activation. It is established that IL-6R~ 
dimerization is required for signal transduction (18). Stahl 
and Yancopoulos (19) postulated a general model for IL-6-1ike 
cytokines, in which ~/chain dimerization is induced by a mono- 
meric cytokine. In this model, IL-6 has three receptor-binding 
sites: an o~ chain binding site and two ~ chain binding sites, 
to which the oe and fl chains sequentially associate  to form 
an active signal transduction complex. Recently, however, 
evidence was obtained in experiments with slL-6Rol and slL- 
6RB,  that the active high affinity IL-6R might consist of 
a hexameric complex of two molecules of each IL-6, IL-6Ra, 
and IL-6RB (20). In this complex, each IL-6 molecule binds 
to an IL-6Rcr molecule. Although IL-6 binding to IL-6Rol 
might induce a conformational change in this chain leading 
to B chain association, for formation of the hexameric com- 
plex, contacts between the IL-6 molecules themselves and 
between each IL-6 and IL-6tL8 molecule might be required. 
The mutations  in  the IL-6.fll-3  regions have little or  no 
effect on IL-6Roe binding (8, 9,  17, and Fig.  2). Moreover, 
the mutations in the ~1 and ~  regions do not seem to affect 
the overall conformation of IL-6, because the mutant pro- 
teins also retain reactivity with conformation specific mAb 
and are all  active in bioassays  with  mouse cells  (data not 
shown). It seems likely, therefore, that they affect either di- 
merization of IL-6, or a direct association with IL-6RB. Fur- 
ther experiments are in progress to elucidate the roles of the 
~/1-3 regions in IL-6-receptor interaction. 
IL-6 has been implicated to play a causative role in a wide 
variety of diseases (for a recent review see 21). Accordingly, 
various strategies are currently explored to inhibit IL-6 ac- 
tivity in vivo, including neutralizing IL-6-specific mAb (2, 
22) and anti-IL-6R mAb (22, 23). An IL-6R antagonist, might 
constitute an alternative, additional strategy to specifically 
inhibit in vivo IL-6 activity. Preferably, because of low im- 
munoreactivity, a receptor antagonist  should be a natural 
variant oflL-6, like the naturally occurring receptor antagonist 
of IL-loJB,  IL-1tLA (24),  or a small (synthetic) IL-6-in- 
hibiting compound. However, no such specific inhibitors of 
IL-6 activity have been described to date.  An advantage of 
using an IL-6K antagonist for therapy could be that it might 
not induce the accumulation of wt IL-6 in the circulation, 
as has been observed both in phase I  trials with anti-IL-6 
mAb and in animal studies (3,  5,  25).  Also,  an IL-6R an- 
tagonist  targets both the membrane-bound as well as the 
soluble form of IL-6Rc~.  In contrast to the soluble forms 
of other cytokine receptors which often inhibit cytokine ac- 
tivity, slL-6Rol can associate with and trigger signal trans- 
duction through IL-6RB, when complexed to IL-6 (13). In- 
creased levels of slL-6Roe have been detected in patients with 
IL-6-induced Myeloma  Cell Growth HIV infection (26) and with multiple myeloma (27) and have 
been suggested to contribute to the disease processes. From 
our experiments it can be deduced that the possible therapeu- 
tical use of an antagonistic IL-6 mutant protein will require 
high  doses  of the  molecule.  Depending  on  the  assay,  a 
103-10S-fold molar excess over wt IL-6 is needed for com- 
plete inhibition (8, see Figs. 3 and 4). These doses are com- 
parable,  however,  to the therapeutic doses of IL-1RA (28). 
Whether it is possible to improve the antagonistic capacity 
of IL-6 mutant proteins by introduction of additional, yet 
unidentified, substitutions that increase the affinity for IL- 
6Rc~, remains to be established. 
In conclusion, by combining two mutations that reduce 
IL-6 signal transduction but not IL-6R binding, we created 
for the first time an IL-6 variant that is completely inactive 
on human mydoma cells. Increasing the affinity of this mu- 
tant protein for the IL-6Rc~ resulted in an effective IL-6tL 
antagonist. The availability of such an antagonist may offer 
an additional approach to specificaUy inhibit IL-6 activity in 
vivo. 
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